Staphylococcus aureus is an important cause of bloodstream infections 1 and a leading cause of severe health care-associated infections. 2 Infection results in significant morbidity and mortality and longer hospital stays if not treated early with effective antibiotics. 3 The prevalence of methicillin resistance in S aureus causing infection now exceeds 49% in US hospitals and continues to increase. 4 Thus, improved methods are needed for rapid detection and differentiation of methicillin-susceptible S aureus (MSSA) and methicillin-resistant S aureus (MRSA) bacteremia to ensure optimal treatment early in the infection.
We developed, validated, and implemented realtime polymerase chain reaction (PCR) detection of the femA gene for Staphylococcus aureus and the mecA gene for methicillin resistance directly from BACTEC (Becton Dickinson, Sparks, MD) blood culture bottles showing gram-positive cocci in clusters. For the 332 positive blood cultures tested, the assay had 100% sensitivity and specificity for identifying methicillinsusceptible (n = 28) and methicillin-resistant (n = 28) S aureus, and overall was 98% sensitive and 94% specific, with 3 uninterpretable test results when identification of coagulase-negative staphylococci was included. PCR detection yields rapid (2-3 hours) results and accurate identification of S aureus directly from signal-positive blood culture bottle samples.
Staphylococcus aureus is an important cause of bloodstream infections 1 and a leading cause of severe health care-associated infections. 2 Infection results in significant morbidity and mortality and longer hospital stays if not treated early with effective antibiotics. 3 The prevalence of methicillin resistance in S aureus causing infection now exceeds 49% in US hospitals and continues to increase. 4 Thus, improved methods are needed for rapid detection and differentiation of methicillin-susceptible S aureus (MSSA) and methicillin-resistant S aureus (MRSA) bacteremia to ensure optimal treatment early in the infection.
Initial antimicrobial treatment for bacteremia often is based on the results of the Gram stain from a positive blood culture bottle. In 48 to 72 hours, results of conventional culture and susceptibility testing permit a change to pathogenspecific antimicrobial therapy. Although vancomycin remains the treatment of choice for MRSA bacteremia, unnecessary use should be avoided to prevent further emergence of resistance as well as colonization or infection by organisms such as vancomycin-resistant enterococci. In addition, treatment of MSSA infections with vancomycin might be inferior to treatment with antistaphylococcal penicillins. 5 The earlier one knows whether the positive blood culture contains S aureus and whether it is methicillin-resistant or susceptible, the more quickly appropriate therapy can be initiated. cocci in clusters, an aliquot was taken from the bottle for real-time polymerase chain reaction (PCR 6, 7 The blood aliquot for real-time PCR was stored at 4°C for up to 24 hours when 200 µL was removed and applied to a Generation Capture Column (Gentra, Minneapolis, MN) and washed following the manufacturer's protocol. The DNA was eluted off the column in 50 to 100 µL of elution solution and used directly in real-time PCR. Extracted DNA (2 µL) was added to a hot-start reaction mixture for each test. The final 20 µL real-time PCR reaction contained 1× LightCycler FastSart DNA Master SYBR Green I (Roche Applied Science, Indianapolis, IN), 2% DMSO (Sigma, St Louis, MO), 5 mmol/L of magnesium chloride, and for the femA test, 0.25 µmol/L of each primer femA-2F and femA-2R, 8 which were designed to amplify a uniquely conserved region of the femA gene found only in S aureus, or for the mecA test, 0.5 µmol/L of each primer mecA4 up: 5'-AAGCGACTTCACATC-TATTAGGTTAT and mecA4 dn: 5'-TATATTCTTCGTTACT-CATGCCATAC, yielding a 402-base-pair product. Included in each run for both tests were blank (water), negative (methicillin-susceptible Staphylococcus epidermidis), and positive (MRSA) controls.
Real-time PCR was accomplished using the LightCycler (Roche Applied Science), and the conditions consisted of an initial step at 95°C for 10 minutes followed by an amplification program for 40 cycles of 3 seconds at 95°C, 5 seconds at 61°C, and 20 seconds at 72°C with fluorescence acquisition at the end of each extension. The amplification program was followed immediately by a melt program consisting of 1 minute at 95°C, 1 minute at 65°C, and a gradual increase to 90°C at a rate of 0.2°C per second with fluorescence acquisition at each temperature transition. During test development, criteria were established that a positive result for femA or mecA was indicated by a cycle threshold (C T ) of 30 or less, an indeterminate result (requiring a repeated assay) for a C T of 31 to 35, and a negative result for a C T of more than 35. The melt temperatures for these 2 targets were 79°C ± 1°C.
Results
The initial validation was done using 10 samples of each of the following organisms: MRSA, MSSA, methicillinresistant coagulase-negative staphylococci (MRCNS), methicillin-susceptible coagulase-negative staphylococci, and nonstaphylococcal organisms using positive blood culture bottles from 50 unique patients. Real-time PCR results matched culture results for all MRSA, MSSA, and MRCNS and showed no amplification for all methicillin-susceptible coagulase-negative staphylococci and nonstaphylococcal organisms. Of note, one potential limitation of detection directly from clinical specimens is a misleading real-time PCR result of MRSA from a mixed MSSA and MRCNS bacteremia. We addressed this possible situation by determining the amplification efficiency of the femA and mecA PCR reactions. Based on 10-fold serial dilutions of the control MRSA strain, both assays were shown to have similar amplification efficiencies (data not shown). Therefore dividing the femA C T value by the mecA C T value would give a C T ratio that could be used to differentiate an MRSA result from a mixture of MSSA and MRCNS. By using this strategy, a specimen can be called positive for MRSA only if the femA/mecA C T ratio was between 0.9 and 1. Table 1) . Comparison of real-time PCR showed complete correlation with culture for all MRSA and MSSA cases. All MRCNS detected by real-time PCR were confirmed to be coagulase-negative staphylococci (CNS) by culture, but susceptibility testing was performed for only 69 of these. For the 3 samples, 2 for femA and 1 for mecA, that were identified as equivocal, the C T was repeatedly in the indeterminate zone, and these grew CNS in culture. Two samples contained both MRSA and CNS and were identified correctly using our C T ratio rule (ratios of 1.00 and 0.94).
Based on the lack of results for 3 of 332 samples, the assay has an indeterminate rate of 0.90%. Analysis of the 329 samples with femA results found the femA test had a sensitivity and specificity of 100%. For the 90 samples that had CNS with susceptibility testing performed, the mecA test had a sensitivity of 97% and a specificity of 86%, although the actual results might be better because the current phenotypic assay for methicillin resistance in CNS can provide false-positive and false-negative test results. 9 When femA and mecA test results were combined, the overall assay for the 329 tests showed a sensitivity of 98% and a specificity of 94% ❚Table 3❚.
Discussion
The use of PCR has increased the speed and accuracy for identification of S aureus and confirmation of MRSA by detection of mecA. 10 It is important to note that our assay correctly detected all MSSA and MRSA directly from signalpositive blood culture bottles. For the 3 blood samples with discrepant results (femA-and mecA-; identified by culture as MRCNS), based on our reporting format (Table 2) , the discrepant results would not have led to a therapeutic error. In addition, for the 3 indeterminate samples, which were considered contaminants on clinical grounds, the only results reported were from traditional culture that detected CNS.
For the routine diagnostic laboratory, a multiplex PCR assay using detection of the mec and fem genes has been suggested as one approach to rapidly identify MRSA from cultures. This was found to be more accurate and sensitive than routine, culture-based analysis, with results available from the initial use of this technology in 24 hours. 11 Similar suggestions have been made for the routine diagnostic laboratory to speed the accurate detection of MRSA in blood cultures, 12 including the use of real-time PCR for this application. 13 Since implementing this described protocol in routine practice, we have tested 332 blood culture bottles by a real-time PCR assay that detected all MSSA and MRSA cases within a possible timeframe of 2 to 3 hours after the bottle was identified as positive. This testing was performed daily initially by 2 technologists from the molecular epidemiology section of clinical microbiology, and now it is run by the technologists in the molecular diagnostics laboratory. The addition of this realtime PCR test to blood cultures has increased the workload for the molecular diagnostics laboratory by 1 run a day that costs $8.00 (reagents and supplies only) per blood sample and has minimally increased the workload for microbiology but greatly increased the speed of reporting results.
Other testing strategies such as a multiplex assay and the addition of an internal control can be used during PCR assay development. However, each additional set of primers adds to the cost of the test and also might reduce detection sensitivity. Our assay was able to accurately address the particular question we were interested in: whether S aureus or MRSA was present in the blood culture of the patient; and the assay answered the question at a very reasonable expense. Therefore, the detection of additional targets was not needed. With the benefit of obtaining reliable results in a few hours as opposed to days, real-time PCR can be used for rapid, accurate detection of MSSA and MRSA bacteremia that can lead to optimal therapeutic treatment at the earliest time.
